CROSSJECT (EPA:ALCJ) | WebDisclosure

Basculer en Français

9480	Companies
185535	Keywords
117927	Articles
99378	Press releases

Home
Companies
CROSSJECT

PRESS RELEASE

published on 05/20/2025 at 07:30, 6 months 16 days ago

CROSSJECT prepares for the launch of a capital increase with preferential subscription rights of around 5 million euros in preparation for commercial and production activities linked to EUA approval
CROSSJECT plans 5 million euros capital increase, may increase to 5.8 million euros, Gemmes Venture to guarantee 75% of initial amount, Heights Capital Management supports offer

Capital Increase Crossject Gemmes Venture Heights Capital Management EUA Approval
BRIEF

published on 05/07/2025 at 07:35, 6 months 29 days ago

CROSSJECT: Progress in the EUA authorization application for ZEPIZURE®

FDA USA ZEPIZURE® BARDA CHEMPACK
BRIEF

published on 05/07/2025 at 07:35, 6 months 29 days ago

CROSSJECT : Progrès dans la demande d'autorisation EUA pour ZEPIZURE®

FDA ZEPIZURE® BARDA EUA CHEMPACK
PRESS RELEASE

published on 05/07/2025 at 07:30, 6 months 29 days ago

CROSSJECT fait un point sur les dernières avancées dans le dépôt de la demande EUA de ZEPIZURE®
CROSSJECT provides updates on the EUA filing of ZEPIZURE® for FDA Emergency Use Authorization in June 2025, supporting U.S. CHEMPACK program against chemical threats

FDA Crossject ZEPIZURE EUA Filing CHEMPACK Program
BRIEF

published on 03/27/2025 at 07:35, 8 months 9 days ago

CROSSJECT publie ses résultats financiers 2024

Résultats Financiers Partenariats Situation De Trésorerie ZEPIZURE® Dépôt Auprès De La FDA
BRIEF

published on 03/27/2025 at 07:35, 8 months 9 days ago

CROSSJECT Publishes 2024 Financial Results

Financial Results Cash Position Partnerships FDA Filing ZEPIZURE®
PRESS RELEASE

published on 03/27/2025 at 07:30, 8 months 9 days ago

CROSSJECT reports financial results for 2024
CROSSJECT reports financial results for 2024 and progress in clinical and regulatory activities, recruitment of COO, and increased cash position. Key achievements and future plans outlined

Financial Results Cash Position Clinical Activities Crossject Regulatory Development
BRIEF

published on 03/25/2025 at 07:35, 8 months 11 days ago

Strategic partnership between CROSSJECT and ETON PHARMACEUTICALS

Eton Pharmaceuticals Crossject ZENEO® Hydrocortisone Adrenal Insufficiency
BRIEF

published on 03/25/2025 at 07:35, 8 months 11 days ago

Partenariat stratégique entre CROSSJECT et ETON PHARMACEUTICALS

Eton Pharmaceuticals Crossject ZENEO® Hydrocortisone Insuffisance Surrénale
PRESS RELEASE

published on 03/25/2025 at 07:30, 8 months 11 days ago

CROSSJECT fait le point sur sa collaboration avec ETON PHARMACEUTICALS, Inc. et sur le programme ZENEO® Hydrocortisone dans le domaine de l'insuffisance surrénale
CROSSJECT renforce sa collaboration avec ETON PHARMACEUTICALS pour le programme ZENEO® Hydrocortisone dans l'insuffisance surrénale, avec des depôts de dossiers prévus à partir de S2 2026

Collaboration Eton Pharmaceuticals Crossject Insuffisance Surrénale ZENEO® Hydrocortisone

Accesswire

Published on 12/05/2025 at 19:50, 22 minutes ago

Gold, Rare Earth Minerals, Digital Assets: The Market Just Realized SMX Sits in All Three
Published on 12/05/2025 at 19:20, 52 minutes ago

The Multi-Sector Validation Shock: Why SMX Became Impossible for Markets to Ignore
Published on 12/05/2025 at 18:45, 1 hour 27 minutes ago

Four Global Markets, One Engine: SMX Just Redefined What a Supply Chain Can Prove
Published on 12/05/2025 at 18:20, 1 hour 52 minutes ago

NuRAN Announces Intention to Complete Consolidation in Preparation to the Restructuring Transaction
Published on 12/05/2025 at 18:00, 2 hours 12 minutes ago

SMX: A New Supply Chain Reality in the World's Four Largest Markets

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 18:58, 1 hour 14 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 1 hour 46 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 1 hour 57 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:51, 2 hours 20 minutes ago

Issue of Equity
Published on 12/05/2025 at 17:46, 2 hours 26 minutes ago

Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds

Les Echos

Published on 12/05/2025 at 17:18, 2 hours 54 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 2 hours 54 minutes ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 5 hours 1 minute ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 5 hours 1 minute ago

Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 6 hours 13 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE

View all LES ECHOS COMFI WIRE